Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Antoni Ribas, M.D., Ph.D.

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology

Dr. Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA.

He is a member of the American Society of Clinical Investigation (ASCI). Antoni is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA, which have been published in major journals such as The New England Journal of Medicine, Nature, Nature Medicine and Proceedings of the National Academy of Sciences. His NIH, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several new agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), dabrafenib (Tafinlar), and trametinib (Mekinist).